Literature DB >> 10095149

Pseudomembranous colitis: causes and cures.

C M Surawicz1, L V McFarland.   

Abstract

Clostridium difficile is the most common nosocomial pathogen of the gastrointestinal tract and has increased in frequency over time. Typical symptoms of C. difficile infection include diarrhea, which is usually nonbloody, or colitis associated with severe abdominal pain, fever and/or gross or occult blood in the stools. Pseudomembranous colitis (PMC), the severest form of this disease, occurs as a result of a severe inflammatory response to the C. difficile toxins. This review focuses on PMC, as this severe form is associated with the greatest medical concern. Diagnosis rests on detection of C. difficile in the stool, either by culture, tissue culture assay for cytotoxin B or detection of antigens in the stool by rapid enzyme immunoassays. Oral therapy with metronidazole 250 mg 4 times a day for 10 days is the recommended first-line therapy. Vancomycin is also effective, but its use must be limited to decrease the development of vancomycin-resistant organisms such as enterococci. Vancomycin (125-500 mg 4 times a day for 10 days) should be limited to those who cannot tolerate or have not responded to metronidazole, or when metronidazole use is contraindicated, as in the first trimester of pregnancy. A therapeutic response within a few days is usual. Recurrence of symptoms after antibiotics occurs in 20% of cases and is associated with persistence of C. difficile in the stools. Further recurrences then become more likely. Therapy with antibiotics in a pulsed or tapered regimen is often effective as are efforts to normalize the fecal flora. The yeast Saccharomyces boulardii has been proven in controlled trials to reduce recurrences when given as an adjunct to antibiotic therapy. Careful hand washing and environmental decontamination are necessary to prevent epidemics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10095149     DOI: 10.1159/000007633

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  23 in total

1.  Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Authors:  J H Boone; M Goodykoontz; S J Rhodes; K Price; J Smith; K N Gearhart; R J Carman; T M Kerkering; T D Wilkins; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

2.  Pseudomembranous Colitis Caused by C. difficile.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-06

3.  Characterization of the Dynamic Germination of Individual Clostridium difficile Spores Using Raman Spectroscopy and Differential Interference Contrast Microscopy.

Authors:  Shiwei Wang; Aimee Shen; Peter Setlow; Yong-qing Li
Journal:  J Bacteriol       Date:  2015-05-04       Impact factor: 3.490

4.  Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.

Authors:  A P Limaye; D K Turgeon; B T Cookson; T R Fritsche
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.

Authors:  C B Kurtz; E P Cannon; A Brezzani; M Pitruzzello; C Dinardo; E Rinard; D W Acheson; R Fitzpatrick; P Kelly; K Shackett; A T Papoulis; P J Goddard; R H Barker; G P Palace; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

6.  Fulminant Pseudomembranous Colitis Leading to Clostridium Paraputrificum Bacteremia.

Authors:  Asim Haider; Fareeha Alavi; Ayesha Siddiqa; Hafsa Abbas; Harish Patel
Journal:  Cureus       Date:  2021-03-08

Review 7.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

8.  [Antibiotic induced diarrhea and pseudomembranous colitis].

Authors:  C Greb; T Kalem; T Kälble
Journal:  Urologe A       Date:  2002-12-19       Impact factor: 0.639

9.  Stool therapy may become a preferred treatment of recurrent Clostridium difficile?

Authors:  Dinesh Vyas; Heidi E L'esperance; Arpita Vyas
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

10.  Bile salts and glycine as cogerminants for Clostridium difficile spores.

Authors:  Joseph A Sorg; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2008-02-01       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.